ENLIVEN THERAPEUTICS INC
ELVNNASDAQ🏆 #1582 by market capEarnings Nov 18US Equity
$44.78▲ $1.07 (+2.44%)
Pre-market · at closeTrack ELVN
Get earnings, price moves & breaking news on Telegram
24h▲ 2.4%
7d▲ 6.6%
14d▲ 15.0%
30d▼ 3.8%
ytd▲ 190.9%
1y▲ 97.7%
🏦Market Cap
$3.28B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $43.69 – $44.89
- 52-Week Range
- $14.79 – $62.32
- Volume (shares)
- 72,624
- Avg Volume (shares)
- —
- Shares Outstanding
- 73.3M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.67
- Dividend Yield
- —
ENLIVEN THERAPEUTICS INC
ELVNFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout ENLIVEN THERAPEUTICS INC
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
19 analysts
Strong Buy7
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.